Ronit Mazor
Overview
Explore the profile of Ronit Mazor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mazor R, King E, Onda M, Cuburu N, Addissie S, Crown D, et al.
Proc Natl Acad Sci U S A
. 2018 Jan;
115(4):E733-E742.
PMID: 29311317
Protein-based drugs are very active in treating cancer, but their efficacy can be limited by the formation of neutralizing antidrug antibodies (ADAs). Recombinant immunotoxins are proteins that are very effective...
12.
Mazor R, Kaplan G, Park D, Jang Y, Lee F, Kreitman R, et al.
Cell Immunol
. 2017 Jan;
313:59-66.
PMID: 28087047
LMB-2, is a potent recombinant immunotoxin (RIT) that is composed of scFv antibody that targets CD25 (Tac) and a toxin fragment (PE38). It is used to treat T cell leukemias...
13.
Mazor R, Addissie S, Jang Y, Tai C, Rose J, Hakim F, et al.
AAPS J
. 2016 Nov;
19(1):117-129.
PMID: 27796910
Identification of helper T-cell epitopes is important in many fields of medicine. We previously used an experimental approach to identify T-cell epitopes in PE38, a truncated bacterial toxin used in...
14.
Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, et al.
Oncotarget
. 2016 May;
7(21):29916-26.
PMID: 27167198
Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a portion of a protein toxin....
15.
Mazor R, Onda M, Pastan I
Immunol Rev
. 2016 Feb;
270(1):152-64.
PMID: 26864110
Recombinant immunotoxins (RITs) are chimeric proteins designed to treat cancer. They are made up of an Fv or Fab that targets an antigen on a cancer cell fused to a...
16.
Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I
Cell Mol Immunol
. 2015 Oct;
14(5):432-442.
PMID: 26477977
Antibodies against the toxin portion of recombinant immunotoxins (RIT) reduce their efficacy and pose a potential safety risk. To overcome this problem we mutated the very immunogenic immunotoxin SS1P to...
17.
Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, et al.
Mol Cancer Ther
. 2015 Oct;
14(12):2789-96.
PMID: 26443804
SS1P is a recombinant immunotoxin (RIT) that targets mesothelin. It consists of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. In clinical studies, it has produced dramatic...
18.
Mazor R, Tai C, Lee B, Pastan I
J Immunol Methods
. 2015 Jun;
425:10-20.
PMID: 26056938
The ability to identify immunogenic determinants that activate T-cells is important for the development of new vaccines, allergy therapy and protein therapeutics. In silico MHC-II binding prediction algorithms are often...
19.
King C, Garza E, Mazor R, Linehan J, Pastan I, Pepper M, et al.
Proc Natl Acad Sci U S A
. 2014 May;
111(23):8577-82.
PMID: 24843166
Immune responses can make protein therapeutics ineffective or even dangerous. We describe a general computational protein design method for reducing immunogenicity by eliminating known and predicted T-cell epitopes and maximizing...
20.
Mazor R, Eberle J, Hu X, Vassall A, Onda M, Beers R, et al.
Proc Natl Acad Sci U S A
. 2014 May;
111(23):8571-6.
PMID: 24799704
Nonhuman proteins have valuable therapeutic properties, but their efficacy is limited by neutralizing antibodies. Recombinant immunotoxins (RITs) are potent anticancer agents that have produced many complete remissions in leukemia, but...